Trial Profile
Long-term study of KW-0761 in patients with HAM
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary)
- Indications HTLV-I infections; Tropical spastic paraparesis
- Focus Adverse reactions; Expanded access
- 01 Aug 2023 Results of post hoc analysis (from studies UMIN000019942 and UMIN000012655) assessing the therapeutic effect of mogamulizumab on gait function by comparing it with contemporary control data from a HAM/TSP patient registry published in the Brain
- 02 Dec 2015 New trial record